dolasetron (Anzemet)
Jump to navigation
Jump to search
Introduction
Tradename: Anzemet (FDA approved 2003)
Indications
- nausea/vomiting associated with chemotherapy (FDA recommends against its use in this context)[2]
- pre-operative nausea/vomiting
Dosage
Oral & injection
Adverse effects
- headache
- fever (with injection)
- diarrhea
- bradycardia
- QT prolongation
- torsades de pointes (with injection)
Mechanism of action
- 5HT3 receptor antagonist
More general terms
References
- ↑ Prescriber's Letter 11(6):34 2004
- ↑ 2.0 2.1 FDA MedWatch Dec 17, 2010 Anzemet (dolasetron mesylate): Drug Safety Communication
Reports of Abnormal Heart Rhythms http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237341.htm - ↑ http://www.Anzemet.com